⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMRX News
Immuneering Corporation Class A Common Stock
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
globenewswire.com
IMRX
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
globenewswire.com
IMRX
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
globenewswire.com
IMRX